Anticoagulants, Thrombolytics, and Antiplatelet Drugs

- Arterial and venous thrombosis have an important impact on worldwide morbidity and mortality .

- Worldwide, >10 million deaths per annum are caused by **arterial thrombotic** events (ischaemic stroke, heart disease, and peripheral gangrene.(
- **Platelets** are the key prothrombotic element in arterial thrombosis, forming aggregates interconnected by fibrin .
- **Antiplatele**t treatment can counteract this process .

- Half a million deaths related to **venous thromboembolism** occur in the European Union per year.
- Their uses include the treatment or prevention of venous thromboembolism and atrial fibrillation.
- For acute treatment of venous thromboembolism and during revascularization therapy, immediately acting **Anticoagulants** are the drugs of choice to prevent or treat these conditions

Drugs used in Thromboembolic Disease

- **Anticoagulants:**
  - Factor inhibitors: e.g. Heparin, Rivaroxaban.
  - Factor synthesis inhibitors: e. g. Oral anticoagulants.
- **Fbrinolytic Drugs:**
  - Streptokinase.
  - Urokinase.
  - ASPAC .
  - Tissue-type Plasminogen Activators (t-PA:(
    Ateplase.
- **Antiplatelet Drugs:**
  - Aspirin.
  - Dipyridamole.
  - Sulphinpyrazone.

Drugs Used to Treat Clotting Disorders




Contact factors
XIa
IXa
VIIIa
Tissue factor, VIIa
Xa
Va
II
IIa
fibrinogen
fibrin clot
Intrinsic pathway (PTT)
Extrinsic pathway (PT)



FIGURE 34–1 Thrombus formation at the site of the damaged vascular wall (EC, endothelial cell) and the role of platelets and clotting factors. Platelet membrane receptors include the glycoprotein (GP) Ia receptor, binding to collagen (C); GP Ib receptor, binding von Willebrand factor (vWF); and GP IIb/IIIa, which binds fibrinogen and other macromolecules. Antiplatelet prostacyclin (PGI_2) is released from the endothelium. Aggregating substances released from the degranulating platelet include adenosine diphosphate (ADP), thromboxane A_2 (TXA_2), and serotonin (5-HT). Production of factor Xa is detailed in Figure 34–2. (Redrawn and reproduced, with permission, from Simoons ML, Decker JW: New directions in anticoagulant and antiplatelet treatment. [Editorial.] Br Heart J 1995;74:337.)

Physiological Inhibitors of Clotting Mechanisms

Inhibitor	Target
Antithrombin	Inhibits factor IIa, IXa and Xa.
Protein C	Inactivates factor Va and VIIIa
Protein S	Cofactor for activation of factor C
Tissue factor pathway inhibitor (TFPI (	Inhibits activity of factor VIIa.
Plasmin	Lyses fibrin into fibrin degradation products.

Anticoagulant drugs

- **Indirect thrombin inhibitor**
- UFH
- LMWH
- Fondaparinux
- **Direct thrombin /factor X inhibitor (DTI(**
- Parenteral: Lepirudin / Bivalirudin
- Oral: Rivaroxaban / Apixaban / Edoxaban / Dabigatran
- **Warfarin**

Unfractionated Heparin UFH

Mechanism of Action:

- **The anticoagulant effect of UFH is mediated through binding to antithrombin.**
- **UFH accelerates the anticoagulant action of antithrombin 100 -1,000 times.**
- **Antithrombin inhibits factor IIa, IXa, Xa, and XIIa activity.**



FIGURE 34–4 Cartoon illustrating differences between fondaparinux, low-molecular-weight heparins (LMWH), and high-molecular-weight heparin (HMWH, unfractionated heparin). Activated antithrombin III (AT III) degrades thrombin, factor X, and several other factors. Binding of these drugs to AT III can increase the catalytic action of AT III 1000-fold. The combination of AT III with unfractionated heparin increases degradation of both factor Xa and thrombin. Combination with fondaparinux or LMWH more selectively increases degradation of Xa.

- It is preferred to administer UFH by **continuous intravenous infusion** .

- The onset of action of UFH after **SC injection** is 1 - 2 hours, peaking at 3 hours.

- **Intramuscular** administration should NOT be used because of the risk of **bleeding & hematomas**. (Absolute contraindication (

- UFH has a dose-dependent half-life of ~ 30 - 90 minutes, because its elimination follows **zero-order kinetics.**

Adverse Effects:

1. **bleeding :**

- ***Protamine sulfate*** (antidote of heparin) in a dose of 1 mg per 100 units of UFH (maximum of 50 mg) can be administered via slow intravenous infusion to reverse the anticoagulant effects of UFH .
- Protamine sulfate neutralizes UFH in 5 minutes, and action persists for 2 hours

.2. Significant bone loss and osteoporosis when used for more than 6 months

3 .Heparin-induced thrombocytopenia (HIT :(

- HIT is caused by antibodies that bind to complexes of heparin and platelet factor 4 (PF.(4

- These antibodies are prothrombotic and activate platelets this will cause thrombotic thrombocytopenia due to platelet consumption .

- Leads to arterial thromboembolic events .

- Occur in 5 - 10 days after initiation of UFH. It takes this much time to produce these antibodies .

- If a patient develops HIT, this patient cannot take any heparin in the future, not even LMWH or fondaparinux. (HIT will develop even faster due to memory B cells, more severe(

- When using unfractionated heparin, 2 parameters require monitoring, **APTT** (Activated partial thromboplastin time) and **platelet count** to detect HIT as early as possible .

- APTT shouldn't increase more than two/three times normal, and not more than that depending on the severity of the thrombosis

Drug–drug Interactions:

- Other anticoagulant, thrombolytics, antiplatelet agents, aspirin, NSAIDs, dipyridamole, or sulfinpyrazone enhance bleeding risk.

Pharmacologic activity of unfractionated heparin, low-molecular-weight heparins (LMWHs), and fondaparinux



Low-Molecular-Weight Heparins (LMWHs(

)Enoxaparin, Dalteparin:(

- LMWH is produced by depolymerization of UFH.
- Have ~ one-third the mean UFH molecular weight.

Advantages include:

a) predictable anticoagulation dose response.
b) improved subcutaneous bioavailability.
c) dose-independent elimination (first-order.(
d) longer half-life .
e) reduced need for routine laboratory monitoring.

LMWHs

- **Low-molecular-weight heparin prevents thrombus growth and propagation by enhancing and accelerating the activity of antithrombin against factor Xa.**
- **Because of smaller chain lengths, LMWH has limited activity against thrombin (IIa .(**

LMWHs

- **The bioavailability of LMWH is ~ 90% after SC injection .**
- **The peak anticoagulation at 3 - 5 hours.**
- **Mainly eliminated by renal excretion .**
- **The half-life of LMWHs is ~ 3 - 6 hours .**
- **Half-life may be prolonged in patients with renal impairment.**

Monitoring

- Weight-based dosing of the LMW heparins results in predictable pharmacokinetics and plasma levels in patients with normal renal function. Therefore, LMW heparin levels are not generally measured except in the setting of renal insufficiency, obesity, and pregnancy. LMW heparin levels can be determined by anti-Xa units. Peak therapeutic levels should be0.5–1 unit/mL for twice-daily dosing, determined 4 hours afteradministration, and approximately 1.5 units/mL for once-daily dosing.

LMWHs

Adverse Effects:

1. **Bleeding.**

- **IV protamine sulfate can be administered as antidote .**

2. **HIT is three times lower than that observed with UFH .**

- **LMWH should be avoided in patients with HIT, because of cross reactivity with antibodies.**

.3 Osteoporosis and osteopenia.

LMWHs

Drug–drug Interactions:

- **Other anticoagulant, thrombolytics, antiplatelet agents, aspirin, NSAIDs, dipyridamole, or sulfinpyrazone enhance bleeding risk.**

Fondaparinux

- **Fondaparinux is a synthetic molecule consisting of the active pentasaccharide units that bind reversibly to antithrombin .**
- **It inhibits only factor Xa activity.**
- **It is effective in prevention of venous thromboembolism (VTE.(**
- **It is rapidly and completely absorbed following SC administration, peak concentrations ~ 2 hours after a single dose and 3 hours with repeated once-daily dosing .**
- **It is eliminated unchanged in the urine, elimination half-life is ~19 hours.**

Fondaparinux

- **The anticoagulant effect of fondaparinux persists for 2 - 4 days following discontinuation of the drug in patients with normal renal function.**

Fondaparinux

Adverse Effects:

1. Bleeding.
2. Rare cause of HIT.

- No antidote to reverse its antithrombotic activity.

Drug–drug Interactions:

- Other anticoagulant, thrombolytics, antiplatelet agents, aspirin, NSAIDs, dipyridamole, or sulfinpyrazone enhance bleeding risk.

Lepirudin

- **Hirudin is derived from Leech.**
- **Lepirudin is from recombinant DNA technology.**
- **Irreversible inhibitor, inactivates fibrin-bound thrombin.**
- **Used IV or SC.**
- **Monitored by aPTT.**
- **Eliminated by hepatic metabolism and renal excretion, accumulates in renal failure.**
- **Used for thrombosis related to HIT.**
- **No antidote is available.**

Bivalirudin

- **Bivalirudin is a direct thrombin inhibitor .**
- **It is a synthetic congener of the naturally occurring anticoagulant hirudin.**
- **Used IV.**
- **Elimination half-life is ~ 25 min.**
- **Cleared by hepatic and renal elimination and proteolytic cleavage.**
- **It inhibits both circulating and clot-bound thrombin, reversibly.**
- **Thus, it has less bleeding risk than other r-hirudins.**

Bivalirudin

- **It also inhibits thrombin-mediated platelet activation and aggregation.**
- **Used in percutaneous coronary intervention (PCI) and for HIT.**
- **Monitored by "thrombin inhibitor assay" which is better than aPTT because it is NOT affected by antiphospholipid antibodies.**
- **It is contraindicated in severe renal impairment.**

Warfarin

- **Vitamin K in its reduced form is a required cofactor for vitamin K-dependent carboxylation of factors II, VII, IX, and X, as well as the endogenous anticoagulant proteins C and S; which is required for their biologic activity .**
- **Warfarin inhibits the reduction of vitamin K epoxide, reducing the formation of complete functioning clotting factors.**
- **It has NO effect on preformed clotting factors, thus, full antithrombotic effect is NOT achieved for at least 6 days after warfarin therapy initiation .**


Inactive Metabolites
CYP2C9
CYP1A1/2
CYP3A4
Clotting
Functional
Factors
γ-Glu
S-WAFARIN
Vitamin K
(Epoxide)
R-WAFARIN
γ-glutamyl
carboxylase
VKOCR1
Glu
Vitamin K
(Reduced)
ACENOCOUMAROL
V½ 9h.
Pro-Clotting
Factors
CYP4F2
CYP2C9/19
CYP1A2
Hydroxy Vitamin K
Inactive Metabolites

Warfarin

- **The time required for warfarin to achieve its pharmacologic effect is dependent on coagulation protein elimination half-lives (6 hours for factor VII and 72 hours for prothrombin.(**

Half-Lives (hours(

Clotting Factor	
II	72
VII	6
IX	24
X	40
Protein C	8
Protein S	30

Warfarin

- **Because of its narrow therapeutic index, predisposition to drug and food interactions, and exacerbation of bleeding, warfarin requires continuous patient monitoring and education to achieve optimal outcomes.**

Warfarin

Adverse Effects:

1. **Bleeding (mild to life threatening .(**

- **Vitamin K is the antidote, can be given parenteraly or orally; the oral route is preferred in the absence of serious bleeding .**
- **In case of bleeding, warfarin should be temporarily stopped or the dose reduced.**

2. **“Purple toe syndrome” is thought to be the result of cholesterol microembolization into the arterial circulation of the toes.**

Warfarin

3. **Warfarin-induced skin necrosis (due to thrombosis) in the first week of therapy (starts as a painful maculopapular rash and ecchymosis or purpura that progresses to necrotic gangrene.(**

- **Areas of the body rich in subcutaneous fat are most commonly affected (breasts, thighs, buttocks, and abdomen.(**

Warfarin Drug–drug Interactions

Pharmacodynamic Interaction	Mechanism
ASA/NSAIDs	Antiplatelet, GI injury
Clopidogrel/TIclopidine	Antiplatelet
Tramadol	INR elevation (mech. Unknown)
Levothyroxine	Increased catabolism of clotting factors
Vitamin K containing food/Supplements	INR reduction (reverse warfarin mechanism of action)

INR Elevation
Amiodarone
Fluoroquinolones
Trimethoprim/sulfamethoxazole
Metronidazole
Azole antifungals
Statins
Isoniazid
NSAIDs
Sertraline Gemfibrozil
Ethanol
Macrolides
Cimetidine
Omeprazole
Fluorouracil

INR Reduction
Rifampin
Barbiturates
Carbamazepine
Phenytoin
St John's wort
Cigarette smoking
Charcoal broiled food
Cholestyramine (Bile acid binding resins)
Oral contraceptives (Estrogens)

Open this site or link to see tables for more comprehensive description of drug and food interactions with warfarin, if you like.

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/486574

Pharmacogenomics

- CYP2C9 is the hepatic microsomal enzyme responsible for metabolism of the more potent S-enantionmer of warfarin .
- Polymorphisms in CYP2C9 and the gene coding for VKOR (Vitamin K epoxide reductase) explain a substantial proportion of warfarin dose variability between patients .
- Poor metabolizer subtypes have been associated with increased risk of bleeding.
- Warfarin resistance can be due to mutations in the receptor gene.
- For individualized warfarin dosing consult (www.warfarindosing.org .(

Direct Oral Anticoagulants

)DOACs:(

- **Rivaroxaban, apixaban, and edoxaban are potent and selective inhibitors of both free and clot-bound factor Xa.**
- **They do not require antithrombin to exert their anticoagulant effect.**
- **Dabigatran (prodrug) is a selective, reversible, direct factor IIa inhibitor .**
- **These drugs are partially eliminated by the kidney to various extent, and should be used with caution in patients with renal dysfunction.**

Direct Oral Anticoagulants

- **Terminal half-lives ~10 hours for the Factor Xa inhibitors, and 16 hours for dabigatran.**
- **Rivaroxaban and apixaban are substrates of cytochrome CYP3A4, and P-glycoprotein.**

Indications:

1. **The Xa inhibitors rivaroxaban and apixaban can prevent venous thromboembolism (VTE) following hip or knee replacement surgery.**
2. **Dabigatran, rivaroxaban and apixaban can be used for extended VTE treatment after the first 6 months of anticoagulant therapy.**

Direct Oral Anticoagulants

Adverse Effects:

1. **Gastrointestinal complaints.**
2. **Bleeding which ranges from minor – severe & fatal .**

- **Discontinuation of therapy and supportive management.**
- **Activated charcoal may provide some benefits if drug intake occurred within 2 hours of presentation, and dabigatran is hemodializable .**

Direct Oral Anticoagulants

- **Idarucizumab rapidly reverses the dabigatran anticoagulant effect following IV administration.**
- **It binds to dabigatran and its acylglucuronide with higher affinity than that of dabigatran to thrombin.**
- **It is used in life-threatening bleeding and when there is need for urgent surgical intervention .**

Direct Oral Anticoagulants

Drug–drug and Drug–food Interactions:

- DOACs are P-gp substrates and subject to changes in anticoagulant effect when coadministered with P-gp inhibitors or inducers .
- Rivaroxaban and apixaban are subject to interactions involving inhibitors or inducers of CYP3A.4
- Other anticoagulant, thrombolytics, antiplatelet agents, aspirin, NSAIDs, dipyridamole, or sulfinpyrazone enhance bleeding risk.

Thrombolytic Agents



Fibrinolytic system. The schematic shows interactions with coagulation and platelet pathways and sites of action of drugs that modify these systems. (LMHs, low-molecular-weight heparins.)

Thrombolytic Agents

- **The fibrinolytic system dissolves intravascular clots by the action of plasmin, a protease.**
- **Re-establish tissue perfusion.**
- **Not alternative to anticoagulants.**
- **Thrombolytic agents are plasminogen activators, including the "tissue plasminogen activator" (tPA .(**

Thrombolytic Agents

- **First Generation TAs:**

  .1Streptokinase

  .2Urokinase

- **Second & Third Generation TAs:**

  .1tPAs: Alteplase, Reteplase, Tenecteplase.

Streptokinase

- **Produced by Lancefield group C β-hemolytic streptococci.**
- **It is indirectly acting.**
- **Nonenzymatic protein, binds to plasminogen and induces a conformational change that exposes the active site which converts plasminogen to plasmin.**
- **Antibodies from previous streptococcal infection may neutralize activity, thus, it requires a loading dose (LD.(**
- **Adverse Effects:**

Bleeding – systemic lytic state, Allergy, Anaphylaxis, Drug fever .

Tissue Plasminogen Activator (tPA(

- **It binds to fibrin with high affinity and activates plasminogen bound to the clot. i.e fibrin-selective activation.**
- **May activate circulating plasminogen at large doses or with long duration of therapy.**
- **Re-occlusion may be lessened by administration of heparin and antiplatelet drugs.**
- **Given by intravenous infusion.**

Adverse effects: bleeding, allergy.

Thrombolytic Agents

Therapeutic uses:

.1Acute myocardial infarction: within 6 hours of onset, infused over 1-3 hours.

.2Central DVT.

.3Sever PE, or multiple PE.

Infused over 12-72 hours

.4Acute ischemic stroke (??): within 3 hours of onset .

Contraindications: Similar to anticoagulants.

Thrombolytic Agents - Antidotes

Aminocaproic acid, Tranexamic acid:

- **Bind to plasminogen and plasmin, thus preventing their action on fibrin.**
- **Contraindicated in dessiminated Intravascular coagulation (DIC), and bleeding from kidney or ureters.**

Adverse effects: Thrombosis, Myopathy, Hypotension, Nausea.

Antiplatelet Drugs



Platelet activation. Events involved in platelet adhesion and aggregation are shown, with the sites of action of drugs and endogenous mediators. (AA, arachidonic acid; ADP, adenosine bisphosphate; GP, glycoprotein; NO, nitric oxide; TXA_2, thromboxane A_2.)

Antiplatelet Drugs

- **Platelets provide the initial hemostatic plug at the site of vascular injury and participate in atherosclerosis.**

Used for:

1. **Prophylaxis of arterial thrombosis.**
2. **Prophylaxis and management of Myocardial infarction & Ischemic stroke, Within 2 hours of onset.**

- **Administered as adjuncts to thrombolytic therapy along with heparin to maintain perfusion and limit size of infarction.**

Antiplatelet Drugs

Classification:

.1Cyclooxygenase inhibitors: Aspirin.

.2PGI_3 generators: Eicosapentaenoic acid.

.3ADP receptor blockers: Clopidogrel and Ticlopidine.

.4GPIIb/IIIa receptor blockers: Abciximab, Eptifibatide, Tirofiban.

.5Others: Dipyrimadole and Cilostazol.

Aspirin

- Irreversible inhibitor (acetylation of active site) of cyclooxygenase of platelets, thus, blocking the production of thromboxane A_2
- The effect lasts for the life time of the platelet (7-10 days), why?
- Used at low doses (< 325 mg). Higher doses are not beneficial, because of inhibition of PGI_2 production.

Eicosapentaenoic Acid

- **Unsaturated fatty acid present in cold water fish.**
- **Generates PGI_3 and $TXA_{.3}$**
- **PGI_3 is an effective anti-aggregating agent like PGI_2, while TXA_3 is much less active than $TXA_{.2}$**

Clopidogrel, Prasugrel & Ticlopidine

- **Prevent formation of platelet plug & clot retraction.**
- **These drugs irreversibly block the ADP P2Y12 receptor on platelets.**
- **This inhibits ADP-induced expression of platelet membrane GPIIb/IIIa receptor and fibrinogen binding to activated platelets.**
- **Needs 4 days to work, full effect 10 days.**
- **Clopidogrel is a prodrug that requires activation via the cytochrome P450 enzyme isoform CYP2C.19**

Clopidogrel, Prasugrel & Ticlopidine

Therapeutic Uses:

.1Patients who require aspirin but can not take it:

)myocardial infarction, unstable angina pectoris, transient ischemic attacks, ischemic strokes.(

.2Patients with coronary stents, in combination with aspirin.

Clopidogrel, Prasugrel & Ticlopidine

Adverse Effects:

.1Bleeding ((5%

.2Nausea, dyspepsia, diarrhea ((20%

.3Severe Neutropenia ((1%

.4Thrombotic thrombocytopenic purpura

.5Cholestatic hepatitis

- Less with clopidogrel

GPIIb/IIIa Receptor Blockers

- **The platelet GP IIb/IIIa receptor functions as a receptor mainly for fibrinogen and vitronectin but also for fibronectin and von Willebrand factor .**
- **Activation of this complex is the final common pathway for platelet aggregation.**
- **Used in acute coronary syndromes parenterally.**

GPIIb/IIIa Receptor Blockers

Include:

Abciximab: a humanized monoclonal antibody against the receptor.

Eptifibatide: a fibrinogen analog.

Tirofiban: similar to Eptifibatide but smaller molecule.

GPIIb/IIIa Receptor Blockers

Dipyridamole:

- **It is a vasodilator that also inhibits platelet function by inhibiting adenosine uptake and cGMP phosphodiesterase activity .**
- **It has little or no beneficial effect if used alone.**
- **It may be used in combination with aspirin to prevent cerebrovascular ischemia, or with warfarin for primary prophylaxis of thromboemboli in patients with prosthetic heart valves.**

Cilostazol:

- **It is a phosphodiesterase inhibitor that promotes vasodilation and inhibition of platelet aggregation .**
- **It is used primarily to treat intermittent claudication.**